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Synthesis of kinase inhibitors containing a
pentaﬂuorosulfanyl moiety†
Supojjanee Sansook,‡a Cory A. Ocasio, a Iain J. Day, a Graham J. Tizzard, b
Simon J. Coles, b Oleg Fedorov,c James M. Bennett,d Jonathan M. Elkins d and
John Spencer *a
A series of 3-methylidene-1H-indol-2(3H)-ones substituted with a 5- or 6-pentaﬂuorosulfanyl group has
been synthesized by a Knoevenagel condensation reaction of SF5-substituted oxindoles with a range of
aldehydes. The resulting products were characterized by X-ray crystallography studies and were tested for
biological activity versus a panel of cell lines and protein kinases. Some exhibited single digit nM activity.
Introduction
The dysregulation of protein phosphorylation mediated by
protein kinases is key to the progression of a number of
cancers. Unsurprisingly, a number of ATP-competitive kinase
inhibitors are in clinical use and development.1–7 For example,
the oxindole-containing antiangiogenic drug Sunitinib 1, con-
taining a 5-fluorine substituent and a solubilizing side chain
on the pyrrole unit, is in clinical use and superseded
Semaxanib (2, SU5416) (Fig. 1) as well as inspiring a number
of other studies on druglike oxindoles.8–15
Metal-based analogues such as 3, 4 have been described by
our group and show kinase inhibition down to the nM range
and tolerance of a range of substituents at the C-5 position.16,17
Meggers’s group replaced the sugar unit in staurosporine, a
pan-kinase inhibitor with relatively high toxicity and unsuitable for
clinical use, by square planar and octahedral transition metal com-
plexes 5–7, leading to highly potent, selective kinase inhibitors.
This was attributed to the novel “imaginary hypervalent carbon”
geometry enabled by the metal complexes (Fig. 2, 5–7).18–21
The pentafluorosulfanyl group is attracting increasing inter-
est in medicinal chemistry. Displaying strong polarity, high
lipophilicity and good stability under physiological conditions,
an SF5 substituent has often been shown to behave like a CF3
group.22–26 Here we show that a SF5 group can be incorporated
in both classical and metal-based oxindole derivatives, at the
5- or 6-position, leading to analogues displaying kinase inhi-
bition down to the nM range.
Results and discussion
Microwave-mediated Knoevenagel condensations of the com-
mercially-available 5- or 6-SF5-substituted oxindoles 8
27 with
three separate aldehydes led to the products 10–14
(Scheme 1).28
The structures of the pyrrole-containing positional isomers
10 and 11 were confirmed by 1H NMR, 13C NMR spectroscopy,
elemental analysis and mass spectrometry. In their 1H NMR
spectra the most downfield signals were assigned to the
pyrrole-NH groups (δ 11.10–13.40 ppm) due to an intra-
Fig. 1 Oxindole-based kinase inhibitors.
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molecular NH⋯OvC hydrogen bond and further confirmation
of their anticipated Z-configuration and such a hydrogen bond
was provided in the solid state (Fig. 3).29
The related reaction with ferrocene carboxaldehyde
aﬀorded a mixture of stereoisomers 12a and 12b, which were
separated by chromatography. Both isomers were characterized
in the solid state (Fig. 4).
We tested all synthetic compounds against a panel of
kinases in a biochemical assay. Each data point was measured
in duplicate (technical replicates). The potencies of com-
pounds that showed appreciable (approx. 50%) inhibition at
1 μM concentration were established by testing them over a
dose range to determine their IC50 values. Additional kinase
binding studies were performed vs. a select group of function-
ally and structurally divergent kinases including AAK1
(Adaptor-associated protein kinase 1), BMP2K (BMP-2-induci-
ble protein kinase, where BMP is bone morphogenic protein),
GAK (Cyclin G-associated kinase) and STK16 (Serine/threo-
nine-protein kinase 16) (Table 1). In all assays a control of
staurosporine, a known promiscuous kinase inhibitor, was
used.
In the case of a number of kinases, e.g. VEGFR2 (vascular
endothelial growth factor receptor 2) and DYRK2 (Dual-speci-
ficity tyrosine phosphorylation-regulated kinase 2), no appreci-
able inhibition was observed for any of our synthesized com-
pounds, suggesting that we might observe diﬀerences in their
selectivity, i.e. no promiscuity, towards this panel of kinases.
Compound 10 bound to BMP2K with an IC50 of 452 nM
whereas 11 displayed nM potency vs. PDGFR2 (98 nM) and
submicromolar potency vs. VEGFR3 (230 nM). Stereoisomeric
12a and 12b only inhibited DYRK3 in the low micromolar
range. The positional isomers 13 and 14 both inhibited
VEGFR3 with IC50s of 530 and 18 nM respectively whereas the
latter displayed an excellent 3.1 nM IC50 vs. PDGFRα.
The synthesized compounds were next tested in breast
cancer and non-transformed breast cell lines. Compounds 10
and 11 potently inhibited MCF7 and T47D breast cancer cell
proliferation with GC50 values ranging from 0.35 to 3.8 μM
with compound 11 proving superior to compound 10.
MCF7 and T47D cells are luminal A ER+/PR+/HER2− cells
that would normally be responsive to estrogen and progester-
one receptor (ER/PR) antagonists such as tamoxifen and
megestrol respectively, but not to human epidermal growth
factor receptor 2 (HER2) inhibitors. MDA-MB-231 (abbreviated
as MM231) cells are triple negative (ER−/PR−/HER2−) and
cannot be treated with hormone receptor and EGFR (HER2)
inhibitors, making cancer cells such as these refractory to
most treatment strategies. Compounds 10 and 11 may oﬀer
advantages for the treatment of ER+/PR+ cancer cells by poly-
Fig. 2 Staurosporine analogues.
Scheme 1 Microwave-mediated Knoevenagel condensations.
Fig. 3 Solid state structures of 10 and 11.
Fig. 4 Solid state structures of 12a and 12b.
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pharmacologically targeting multiple kinases such as the
receptor tyrosine kinases and other serine/threonine kinases.
Lastly, it is encouraging that normal MCF10A cells were resist-
ant to all inhibitor treatments suggesting these compounds
would have a large therapeutic window (Table 2).
Compound 11, which bears a methylidene indolinone
scaﬀold (Fig. 1), demonstrated its greatest potency against the
receptor tyrosine kinase PDGFRα, which adopts an inactive
conformation according to X-ray crystallographic analysis
(Fig. S1B†); however, an X-ray co-crystal structure containing a
methylidene indolinone-based inhibitor (15, Fig S1†) bound to
the RET kinase domain reveals a type 1 inhibitor binding-
mode, or binding to an active kinase conformation (Fig. S1B†).
Alignment of 15-bound RET with the PDGFRα structure reveals
gross structural shifts between analogous β-hairpins and
Cα-helices, which is not surprising as the active conformation
is generally rigid and condensed and the inactive confor-
mation is generally more open.30 Alignment of the Dasatinib-
bound co-crystal structure of Protein-tyrosine kinase 6 (PTK6),
a non-receptor tyrosine kinase, with the 15-bound RET reveals
that they share a similar, active conformation (Fig. S1C†).
Based on this analysis, it makes sense to use an active kinase
conformation, as the above elements (β-hairpin and Cα-helix)
are proximal to the ATP-binding pocket and likely to have an
impact on binding mode. However, rather than performing
docking studies with RET, we decided that PTK6 would be
superior as this kinase has a threonine gatekeeper residue,
similar to that of PDGFRα, whereas RET has a valine at the
same position. Valine is slightly bigger and more hydrophobic
than threonine, lacking a hydroxyl group compared to threo-
nine, and could drastically perturb interactions necessary for
10 and 11-binding. Furthermore, based on the similarity of 10
and 11 with other type 1 methylidene indolinone inhibitors,
we predicted that docking these compounds to an active PTK6
kinase conformation would yield improved binding energies; a
result confirmed by docking 10 and 11 to the inactive kinase
conformation of PDGFRα (PDB: 5K5X), which reported
higher binding energies, and thus less avid binding, for both
10 and 11.
Against PTK6, both compounds bind in a very similar
manner as seen in Fig. 5 (top panel). We found the SF5 moiety
of 10 and 11 to bind deeply in a predominantly hydrophobic
Table 1 Biochemical kinase assays
Kinasea 10 11 12a 12b 13 14 Staurosporinec
1 IC50 (M) STK16
b 1.76 × 10−5 1.35 × 10−4 nt nt — — 1.14 × 10−7
2 GAKb 3.42 × 10−5 4.76 × 10−7 nt nt — — 1.89 × 10−8
3 BMP2Kb 4.52 × 10−7 1.87 × 10−4 nt nt — — 3.17 × 10−9
4 AAK1b 1.0 × 10−6 1.0 × 10−3 nt nt — — 2.47 × 10−9
5d DYRK3 (h) — — 1.7 × 10−6 2.4 × 10−6 — — 4.5 × 10−8
6 PDGFRα (h) — 9.8 × 10−8 — — — 3.1 × 10−9 1.2 × 10−9
7 FLT-4 (h) (VEGFR3) — 2.3 × 10−7 — — 5.3 × 10−7 1.8 × 10−8 7.8 × 10−10
aUnless stated otherwise, performed in the presence of 10 μM ATP. b Binding displacement assays have no ATP present. cNo activity was observed
for 10–14 vs. KDR kinase (h) (VEGFR2), PDGFRβ kinase (h); DYRK1a (h); DYRK2a (h); FLT-1 kinase (h) (VEGFR1), where staurosporine positive
controls gave IC50s of 2.3 × 10
−9; 2.5 × 10−9; 3.2 × 10−8; 8.3 × 10−7; 2.8 × 10−8 respectively. d Entries 5–7 performed by CEREP (France; http://www.
cerep.fr). nt – not tested. — insuﬃciently active for an IC50 determination.
Table 2 Cellular activity of 10 and 11
GC50
a, μM
Compound MCF7 T47D MDA-MB-231 MCF10A
10 4.8 ± 1 0.49 ± 0.4 na na
11 0.69 ± 0.4 0.35 ± 0.1 na na
a The GC50 value was defined as the amount of compound that caused
50% reduction in cellular proliferation in comparison with DMSO-
treated control and was calculated using GraphPad Prism version 6
software; na = not applicable.
Fig. 5 Docking poses of 10 and 11. Docking was performed using
AutoDock 4.2.6.; Lamarckian Genetic Algorithm empirical free energy
scoring function. PDB format ﬁles for the ligand and kinase domain
were pre-processed using AutoDock Tools 1.5.6.
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pocket next to the gatekeeper residue (Fig. 5 top and bottom
panels). The amide hydrogen of both compounds interacts
with the Met267 backbone; however, note that the attachment
of the SF5 group to position 5 of the oxindole ring forces com-
pound 10 to swing away slightly from the hinge. This may
explain why inhibitor 11 is more potent in cells and in vitro
(PDGFRα & VEGFR3) as the hydrogen bond distance is shorter
for the 11 docking-pose, indicative of a stronger interaction.
Conclusion
A small library of SF5-containing oxindole analogues has been
synthesized. Many products were characterized in the solid
state and assayed vs. a small panel of kinases. Docking studies
predicted eﬀective binding of the SF5 group to a hydrophobic
cleft in the kinase and biochemical assays showed little evi-
dence of promiscuity in the range of analogues synthesized.
This bodes well for the use of the SF5 group in medicinal
chemistry with compound 14 in particular showing low nM
potency against VEGFR3 and PDGFRα kinases.
Experimental
5-(Pentafluorosulfanyl)-1,3-dihydro-indol-2-one and 6-(penta-
fluorosulfanyl)-1,3-dihydro-indol-2-one were obtained from
SpiroChem (https://spirochem.com/sf5.html). Ferrocene car-
boxaldehyde, pyrrole-2-carboxaldehyde and piperidine were
obtained from Sigma-Aldrich. Preparative TLC plates were
obtained from Analtech. Solvents and reagents were purchased
from commercial suppliers and were used without purifi-
cation. All reactions were performed in a fume hood. NMR
spectra were recorded on Varian 500 MHz or 400 MHz spec-
trometers and chemical shifts are reported in ppm, usually
referenced to TMS as an internal standard. LCMS were per-
formed by Shimadzu LCMS-2020 equipped with a Gemini®
5 µm C18 110 Å column and percentage purities were ran over
30 minutes in water/acetonitrile with 0.1% formic acid (5 min
at 5%, 5%–95% over 20 min, 5 min at 95%) with the UV detec-
tor at 254 nm. Mass spectrometry: ESI mass spectra were
obtained using a Bruker Daltonics Apex III, using Apollo ESI
as the ESI source. For EI mass spectra, a Fissions VG Autospec
instrument was used at 70 eV. Analyses are for the molecular
ion peak [M]+ and are given in m/z, mass to charge ratio.
Elemental analyses were conducted by Stephen Boyer (London
Metropolitan University). A CEM Explorer microwave unit was
used for microwave reactions (under fumehood) with the hood
placed down. The following CCDCs have been deposited
for the solid-state structures presented herein: 10 = 154150;




0.5 mmol), pyrrole-2-carboxaldehyde (57.06 mg, 0.6 mmol),
ethanol (5 mL) and cat. piperidine (3 drops) were subjected to
microwave irradiation by ramping to 150 °C and were held at
that temperature for 30 minutes. TLC analysis of the cooled
reaction mixture monitored consumption of starting materials.
The crude reaction mixture was extracted with ethyl acetate
(2 × 10 cm3) and washed with deionised water (10 mL) and
brine (2 × 10 mL), the organic layer was dried using mag-
nesium sulphate then filtered through a cotton wool plug. The
crude mixture was concentrated in vacuo and purified using
silica gel column chromatography using 3 : 7 hexane/diethyl
ether to give an orange solid. The yield was 105 mg, 65%.
Crystallization by mixed solvents, CH2Cl2 and hexane, provided
orange crystals. 1H NMR (DMSO-d6, 500 MHz): δ = 13.22 (1H,
s, NH), 11.30 (1H, s, NH), 8.24 (1H, d, J = 2.3 Hz, CH), 8.11
(1H, s, CH), 7.65 (1H, dd, J = 8.6, 2.2 Hz, CH), 7.44 (1H, d, J =
2.2 Hz, CH), 7.02 (1H, d, J = 8.6 Hz, CH), 6.92 (1H, d, J =
3.6 Hz, CH), 6.41 (1H, dd, J = 3.6, 2.2 Hz, CH). 13C NMR
(DMSO-d6, 126 MHz): δ = 169.9, 147.5, 141.5, 130.0, 129.5,
127.6, 125.9, 124.7, 122.5, 116.7, 115.2, 112.3, 109.6. HRMS-ESI
(m/z) found: 337.0431, calc. for [C13H9F5N2OS + H]
+ 337.0429.
Anal. calcd (%) for C13H9F5N2OS: C, 46.43; H, 2.70; N, 8.33;




0.5 mmol), pyrrole-2-carboxaldehyde (57.06 mg, 0.6 mmol),
ethanol (5 mL) and cat. piperidine (3 drops) were subjected to
microwave irradiation by ramping to 150 °C and were held at
that temperature for 30 minutes. TLC analysis of the cooled
reaction mixture showed consumption of starting materials.
The crude reaction mixture was extracted with ethyl acetate
(2 × 10 mL) and washed with deionised water (10 mL) and
brine (2 × 10 mL), the organic layer was dried using mag-
nesium sulphate then filtered through a cotton wool plug. The
crude mixture was concentrated in vacuo and purified using
silica gel column chromatography using 3 : 7 hexane/ethyl
acetate and trituration with hexane to give brown-orange solid.
The yield was 142 mg, 74%. Crystallization in CH2Cl2 (DCM)
provided orange crystals. 1H NMR (DMSO-d6, 500 MHz):
δ = 13.31 (1H, s, NH), 11.14 (1H, s, NH), 7.99 (1H, s, CH), 7.81
(1H, d, J = 8.6 Hz, CH), 7.53 (1H, dd, J = 8.6, 2.0 Hz, CH), 7.48
(1H, s, CH), 7.26 (1H, d, J = 2.0 Hz, CH), 6.93 (1H, m, CH), 6.43
(1H, dd, J = 3.7, 2.1 Hz, CH). 13C NMR (DMSO-d6, 126 MHz):
δ = 169.5, 138.8, 130.2, 130.0, 129.6, 128.3, 123.1, 119.1, 118.7,
114.7, 112.7, 107.0. HRMS-ESI (m/z) found: 337.0432, calc.
for [C13H9F5N2OS + H]
+ 337.0429. Anal. calcd (%) for
C13H9F5N2OS: C, 46.43; H, 2.70; N, 8.33. Found (%): C, 46.59;
H, 2.61; N, 8.17.
5-Pentafluorosulfanyl-3-ferrocenylindolin-2-one, 12a,b
5-(Pentafluorosulfanyl)-1,3-dihydro-indol-2-one (259.2 mg,
1.0 mmol), ferrocenecarboxaldehyde (256.8 mg, 1.2 mmol),
ethanol (10 mL) and cat. piperidine (6 drops) were subjected to
microwave irradiation and work-up as above. The crude
mixture was concentrated in vacuo and purified using prepara-
Paper Organic & Biomolecular Chemistry






















































































tive TLC using 3 : 7 hexane/ethyl acetate to give fraction 1
(purple solid; 160 mg, 35%) and fraction 2 (red solid; 109 mg,
24%). Crystallization of fraction 1 was by mixed solvents
(CH2Cl2 and hexane) and fraction 2 was by CH2Cl2 alone.
(Z)-12a. 1H NMR (DMSO-d6, 500 MHz): δ = 10.84 (1H, s, NH),
8.23 (1H, s, CH), 7.98 (1H, s, CH), 7.68 (1H, d, J = 8.6, CH),
6.92 (1H, d, J = 8.6 Hz, CH), 5.37 (2H, s, 2CH), 4.69 (2H, s,
2CH), 4.22 (5H, s, Cp). 13C NMR (CDCl3-d, 126 MHz):
δ = 167.7, 141.9, 125.1, 119.3, 116.0, 110.0, 108.4, 74.0, 73.3,
70.0, 60.3, 14.2. HRMS-ESI (m/z) found: 455.0065, calc. for
[C19H14F5FeNOS]
+ 455.0060. Anal. calcd (%) for C19H14F5FeNOS:
C, 50.13; H, 3.10; N, 3.08. Found (%): C, 50.22; H, 3.03; N, 3.07.
(E)-12b. 1H NMR (DMSO-d6, 500 MHz): δ = 10.94 (1H, s, NH),
8.30 (1H, s, CH), 7.76(1H, d, J = 8.4, CH), 7.65–7.71 (1H, m, CH),
7.01 (1H, d, J = 8.4, CH), 4.79–7.81 (4H, m, 4CH), 4.29 (5H, m,
Cp). 13C NMR (CDCl3-d, 126 MHz): δ = 171.1, 141.8, 109.0, 88.2,
72.6, 71.7, 70.2, 60.3, 31.5, 29.6, 22.6, 20.9, 19.0, 14.1, 14.0.
HRMS-ESI (m/z) found: 455.0064, calc. for [C19H14F5FeNOS]
+
455.0060. Anal. calcd (%) for C19H14F5FeNOS: C, 50.13; H, 3.10;
N, 3.08. Found (%): C, 50.27; H, 3.23; N, 3.10.
(Z)-3-(2,4-Dimethyl-5-((5-pentafluorosulfanyl-2-oxoindolin-3-
ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid, 13
5-(Pentafluorosulfanyl)-1,3-dihydro-indol-2-one (106 mg, 0.41
mmol), 3-(5-formyl-1H-pyrrole-3-yl)propanoic acid (97.6 mg,
0.5 mmol), ethanol (6 mL) and piperidine (5 drops) were sub-
jected to microwave irradiation by ramping to 150 °C and were
held at that temperature for 30 minutes. TLC analysis of the
cooled reaction mixture monitored consumption of starting
materials. The crude reaction mixture was concentrated,
washed with hexane and CH2Cl2 to give a brown solid. The
yield was 141 mg, 79%. 1H NMR (DMSO-d6, 500 MHz): δ =
13.46 (1H, s, OH), 8.40 (1H, s, NH), 7.86 (1H, s, NH), 7.55 (1H,
d, J = 8.6 Hz, CH), 6.98 (1H, J = 8.6 Hz, CH), 2.77–2.72 (2H, m,
2CH), 2.62 (2H, t, J = 7.7 Hz, CH2), 2.31 (3H, s, CH3), 2.28–2.22
(2H, s, CH2), 1.48 (3H, s).
13C NMR (DMSO-d6, 126 MHz): δ =
186.1, 174.6, 170.0, 140.1, 136.8, 132.7, 126.7, 126.3, 123.6,
116.2, 110.4, 109.0, 88.3, 88.2, 35.2, 20.0, 12.5, 10.1. HRMS-ESI
(m/z) found: 459.0772, calc. for [C18H17F5N2NaO3S]
+ 459.0772.
Anal. calcd (%) for C18H17F5N2O3S: C, 49.54; H, 3.93; N, 6.42.
Found (%): C, 49.63; H, 4.04; N, 6.48.
(Z)-3-(2,4-Dimethyl-5-((6-pentafluorosulfanyl-2-oxoindolin-3-
ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid, 14
The title compound was prepared by a Knoevenagel conden-
sation reaction. 6-(Pentafluorosulfanyl)1,3-dihydro-indol-2-one
(106 mg, 0.41 mmol), 3-(5-formyl-1H-pyrrole-3-yl)propanoic
acid (97.6 mg, 0.5 mmol), ethanol (6 mL) and piperidine
5 drops were subjected to the microwave irradiation by
ramping to 150 °C and were held at that temperature for
30 minutes. TLC analysis of the cooled reaction mixture moni-
tored consumption of starting materials. The crude reaction
mixture was dried, washed with hexane and CH2Cl2 to give a
brown solid. The yield was 136 mg, 76%. 1H NMR (DMSO-d6,
500 MHz): δ = 13.50 (1H, s, OH), 10.87 (1H, s, NH), 7.90 (1H, d,
J = 8.6 Hz, CH), 7.74 (1H, s, NH), 7.46 (1H, dd, J = 8.6, 2.1 Hz,
CH), 7.24 (1H, d, J = 2.1 Hz, CH), 2.78–7.69 (1H, m, CH),
2.66–2.61 (2H, m, CH2), 2.34–2.27 (6H, m, 2CH3), 2.25 (1H, s,
CH), 1.50 (1H, s, CH). 13C NMR (DMSO-d6, 126 MHz):
δ = 174.5, 169.7, 137.8, 133.2, 130.4, 126.9, 123.9, 117.9, 109.8,
88.3, 88.2, 44.4, 35.1, 23.1, 22.5, 20.0, 12.5, 9.96. HRMS-ESI
(m/z) found: 459.0776, calc. for [C18H17F5N2NaO3S]
+ 459.0772.
Anal. calcd (%) for C18H17F5N2O3S: C, 49.54; H, 3.93; N, 6.42.
Found (%): C, 49.70; H, 4.09; N, 6.56.
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